Accelerated progression of white matter hyperintensities and subsequent risk of mortality: a 12-year follow-up study  by Sabayan, Behnam et al.
lable at ScienceDirect
Neurobiology of Aging 36 (2015) 2130e2135Contents lists avaiNeurobiology of Aging
journal homepage: www.elsevier .com/locate/neuagingAccelerated progression of white matter hyperintensities
and subsequent risk of mortality: a 12-year follow-up study
Behnam Sabayan a,b,*, Jeroen van der Grond a, Rudi G. Westendorp b,d,
Mark A. van Buchem a, Anton J.M. de Craen b,c
aDepartment of Radiology, Leiden University Medical Center, Leiden, The Netherlands
bDepartment of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands
cNetherlands Consortium for Healthy Ageing, Leiden, The Netherlands
dDepartment of Public Health, Copenhagen University, Denmarka r t i c l e i n f o
Article history:
Received 22 December 2014
Received in revised form 20 February 2015
Accepted 3 March 2015





Older subjects* Corresponding author at: Department of Radiolog
Center, PO Box 9600, 2300 RC Leiden, The Netherla
fax: þ31 715 26 8256.
E-mail address: b.sabayan@lumc.nl (B. Sabayan).
0197-4580/$ e see front matter  2015 Elsevier Inc. A
http://dx.doi.org/10.1016/j.neurobiolaging.2015.03.003a b s t r a c t
We examined the association of accelerated progression of white matter hyperintensities (WMH) with
mortality outcomes in 534 older subjects at risk for cardiovascular disease. Using brain magnetic
resonance imaging, volume of WMH was measured 2 times in an average of 33 months apart. After the
second magnetic resonance imaging, occurrence of death was recorded during 12 years of follow-up. In
multivariable analyses, each mL/y increase in global WMH was associated with 1.22-fold (95% conﬁ-
dence interval [CI], 1.09e1.37) higher risk of all-cause mortality, 1.29-fold (95% CI, 1.06e1.56) higher
risk of cardiovascular mortality, and 1.20-fold (95% CI, 1.02e1.40) higher risk of noncardiovascular
mortality. Each mL/y increase in periventricular WMH was associated with 1.22-fold (95% CI, 1.08e37)
higher risk of all-cause mortality and 1.24-fold (95% CI, 1.06e1.44) higher risk of noncardiovascular
mortality. Conversely, deep cortical WMH was only associated with cardiovascular mortality (1.92-fold,
95% CI, 1.12e3.30). Accelerated progression of WMH is linked with mortality risk in old age. Progression
of periventricular WMH associates with noncardiovascular mortality, whereas progression of deep
cortical WMH associates with cardiovascular mortality.
 2015 Elsevier Inc. All rights reserved.1. Introduction
White matter hyperintensities (WMH) are commonly observed
on brain magnetic resonance imaging (MRI) of older subjects
(Soderlund et al., 2003). Neuroimaging studies have shown that
about 80 percent of older people from the general population have
deep cortical WMH and >60 percent have periventricular WMH
(de Leeuw et al., 2001). Increasing evidence supports that higher
loads of WMH are associated with adverse health outcomes
(Debette and Markus, 2010). Despite this evidence and given that
prevalent WMH might basically reﬂect long-term vascular and in-
ﬂammatory insults to the brain (Raz et al., 2012), it is unknown
whether rapid progression of WMH in old age is also associated
with higher risk of mortality.
Previous studies have reported different neuropathological
features for periventricular and deep cortical WMH and also
showed that location of WMH is related to various clinical conse-
quences (Kim et al., 2008). For instance, periventricular (and noty, Leiden University Medical
nds. Tel.: þ31 715 26 4376;
ll rights reserved.deep cortical) WMH is associated with impaired executive function
and processing speed (Seo et al., 2012), whereas subjects with
depression have higher loads of deep cortical WMH (Sheline et al.,
2008). Studies on the association between WMH and mortality
have mainly focused on total WMH, and it is unclear whether
progression of WMH in different anatomical locations shows dif-
ferential association in relation to all-cause, cardiovascular, and
noncardiovascular mortality.
In this study, in a cohort of older subjects at risk for cardiovas-
cular disease, we investigated whether rapid progression of WMH
is linked with a higher risk of all-cause, cardiovascular, and non-
cardiovascular mortality. Furthermore, we tested whether peri-
ventricular and deep cortical WMH show different associations in
relation to mortality outcomes.
2. Methods
2.1. Setting and participants
We included participants from the nested MRI substudy of the
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a
randomized clinical trial investigating the beneﬁts of pravastatin on
Table 1
Baseline characteristics of study participants in relation to WMH progression
Characteristics All (n ¼ 534) Tertiles of total WMH progression
Low (n ¼ 178) Middle (n ¼ 178) High (n ¼ 178) p-valuea
WMH progression
Total, mL/y, median (IQR) 0.20 (0.01, 0.72) 0 (0.04, 0.02) 0.23 (0.11, 0.35) 1.05 (0.71, 1.60)
Periventricular, mL/y, median (IQR) 0.20 (0, 0.72) 0 (0.04, 0.01) 0.22 (0.10, 0.35) 1.04 (0.70, 1.60)
Deep cortical, mL/y, median (IQR) l 0.05 (0, 0.16) 0 (0.01, 0.01) 0.07 (0.01, 0.12) 0.21 (0.06, 0.45)
Sociodemographic factors
Age, y, mean (SD) 74.5 (3.2) 73.7 (3.0) 74.5 (3.2) 75.2 (3.2) <0.001
Men, n (%) 312 (56.4) 109 (61.2) 99 (55.6) 94 (52.8) 0.263
Age left school, y, mean (SD) 15.4 (2.9) 15.4 (2.9) 15.4 (2.7) 15.7 (3.0) 0.603
Current smoker, n (%) 115 (20.8) 33 (18.5) 38 (21.3) 40 (22.5) 0.642
Cardiovascular factors
History of CVD, n (%) 240 (43.4) 66 (37.1) 78 (43.8) 85 (47.8) 0.120
History of stroke or TIA, n (%) 89 (16.1) 21 (11.8) 29 (16.3) 33 (18.5) 0.202
History of CAD, n (%) 67 (12.1) 26 (14.6) 21 (11.8) 19 (10.7) 0.510
Serum cholesterol, mmol/L, mean (SD) 5.7 (0.8) 5.7 (0.8) 5.8 (0.9) 5.7 (0.8) 0.182
Body mass index, kg/m2, mean (SD) 26.7 (3.6) 26.7 (3.5) 26.9 (3.8) 26.5 (3.6) 0.685
Diabetes mellitus, n (%) 91 (16.5) 39 (21.9) 24 (13.5) 28 (15.7) 0.091
Antihypertensive therapy, n (%) 349 (63.1) 104 (58.4) 118 (66.3) 116 (65.2) 0.250
Statin treatment, n (%) 275 (49.7) 96 (53.9) 85 (47.8) 90 (50.6) 0.498
SBP, mmHg, mean (SD) 158 (22) 156 (22) 158 (22) 158 (21) 0.578
DBP, mmHg, mean (SD) 86 (11) 86 (11) 86 (11) 86 (10) 0.980
Cognitive function
MMSE, mean (SD) 28.2 (1.5) 28.2 (1.4) 28.3 (1.5) 28.1 (1.6) 0.317
Key: CAD, coronary artery disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; IQR, inter quartile range; MMSE, Mini-Mental State Examination; SBP, systolic
blood pressure; SD, standard deviation; TIA, transient ischemic attack; WMH, white matter hyperintensities.
a Probability values indicate signiﬁcant difference in tertiles of progression in white matter hyperintensities.
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males or females aged 70e82 years with either pre-existing vascular
diseases or with increased risk of vascular disease because of
smoking, hypertension, or diabetes mellitus. Subjects with conges-
tive heart failure (NewYorkHeart Association class III/IV), signiﬁcant
arrhythmia, and cognitive impairment (Mini-Mental Score Exami-
nation score<24)were not recruited in thePROSPER study. Inclusion
and exclusion criteria of the PROSPER study have been described in
detail elsewhere (Shepherd et al., 1999). A total of 554 Dutch par-
ticipants who completed the trial underwent 2 successiveMRI scans
of the brain. The ﬁrst MRI was during the placebo lead-in period and
the second MRI after an average follow-up of 33 months (range:
35e44 months). In this study, we did not include 20 participants
from theMRI substudywho had incomplete data for baseline and/or
follow-up WMH. There was no signiﬁcant difference between char-
acteristics of the included participants and subjects with missing
values. Because we previously reported that treatment with pra-
vastatin does not inﬂuenceWMH changes (ten Dam et al., 2005) and
accelerated progression of total, subcortical and periventricular
WMH were not related to pravastatin use (Supplementary Table 1),
participants were included from both pravastatin and placebo
groups. In addition, analyses were adjusted for statin treatment. The
institutional review board approved the protocol for the MRI study,
and all participants gave written, informed consent.2.2. MRI scanning
All imaging was performed on an MR system operating at ﬁeld
strength of 1.5 T (Philips Medical Systems, Best, the Netherlands).
Dual fast spin echo (repetition time [TR] ¼ 3000 ms; echo time
[TE]¼ 27/120ms; ﬂip angle¼ 90; slice thickness¼ 3mm; 48 slices;
no interslice gap; ﬁeld of view [FOV] ¼ 220  220 mm; matrix ¼
256  204), ﬂuid-attenuated inversion recovery (FLAIR; TR ¼ 8000
ms; TE¼ 100ms; ﬂip angle¼ 90; slice thickness¼ 3mm; 48 slices;
no interslice gap; FOV ¼ 220  176 mm; matrix ¼ 256  153), and
susceptibility-weighted images (multislice gradient echo sequence;
TR¼ 2593ms; TE¼ 48ms; ﬂip angle¼ 60; slice thickness¼ 6mm;22 slices; interslice gap¼ 6mm;whole brain coverage; FOV¼ 220
198 mm; matrix ¼ 256  176) were obtained from all subjects. The
SIENAX (Structural Image Evaluation, using Normalization, of Atro-
phy for cross-sectional measurement) technique was used to obtain
estimates of total brain parenchymal volume, gray matter and white
matter volume. In summary, SIENAX starts by extracting brain and
skull images from the singlewhole-head input data. The brain image
is then afﬁne-registered toMontrealNeurological Institute 152 space
(by using the skull image to determine the registration scaling), done
primarily to obtain the volumetric scaling factor to be used as
normalization for head size (Smith et al., 2004). Segmentation of
WMH volume was performed automatically using Software for
Neuro-Image Processing in Experimental Research, an in-house
developed program for image processing (Admiraal-Behloul et al.,
2005). This segmentation was based on the T2-weighted and
FLAIR images. WMH were deﬁned as hyperintense lesions on both
proton density and T2-weighted images. WMH connected to the
lateral ventricles were labeled as periventricular WMH, and those
not connected to the lateral ventricleswere labeled as deepWMH. To
correct for incidental inclusion of cerebrospinal ﬂuid and gray
matter, the automatically generated WMH segmentations were
edited manually by 2 trained raters. Moreover, FLAIR hardcopies
were used as a reference to rule out other pathogenesis. To prevent
the possibility of over-reading WMH progression in a direct scan
comparison setting, we analyzed the ﬁrst and second MRIs in
random order. FifteenMRI scanswere segmented twice to assess the
intrarater and inter-rater reliability of the volumetric WMH mea-
surements. Intraclass correlation coefﬁcients for periventricular and
deepWMHvolumeswere all 0.99 (van den Heuvel et al., 2006). Rate
of the progression of WMH was calculated by subtracting WMH
volumes in the baseline session fromWMH in the follow-up session
divided by the years between 2 MRI assessments (mL/y).2.3. Mortality
After the second MRI, participants were followed for occurrence
of mortality until January 1, 2012 in a follow-up period of 12 years.
Fig. 1. Cumulative mortality in relation to white matter hyperintensities (WMH) pro-
gression Kaplan-Meier curves for all-cause, noncardiovascular, and cardiovascular
mortality in tertiles of progression in total white matter hyperintensities (mL/y).
B. Sabayan et al. / Neurobiology of Aging 36 (2015) 2130e21352132We obtained dates of deaths from the Dutch civic registry and
speciﬁc data on causes of death from Statistics Netherlands. In the
Netherlands, death certiﬁcates are issued by the attending physi-
cian or medical examiner. Death certiﬁcates with underlying causes
of death, supported by the medical records, are sent to the Central
Bureau of Statistics. An underlying cause of death is deﬁned as ‘‘the
disease or injury that initiated the train of morbid events leading
directly to death or the circumstances of the accident or violence
which produced the fatal injury’’. The underlying cause of death is
selected from a death certiﬁcate and coded according to theTable 2
Risk of mortality in relation to progression of total white matter hyperintensities
Mortality
All-cause
HRa (95% CI) p-value
Unadjusted model 1.26 (1.15e1.38) <0.001
Age and sex adjusted model 1.26 (1.15e1.39) <0.001
Multivariable adjusted modelb 1.22 (1.09e1.37) 0.001
a Hazard ratios (HRs) are calculated for each mL/y progression in total white matter h
b Adjusted for age, sex, education, body mass index, smoking, serum cholesterol, systo
history vascular diseases, and baseline total white matter hyperintensity.International Classiﬁcation of Diseases and related disorders, 10th
revision, 1992. The high reliability of this method for major cau-
ses of mortality has been established previously (Harteloh et al.,
2010). Coronary heart disease, cancers, cerebrovascular diseases,
respiratory disorders, and dementia and/or neurodegenerative
diseases are the main causes of death among older subjects in the
Netherlands. All the coronary heart diseases and cerebrovascular
accidents were categorized in the cardiovascular group and cancers,
respiratory disorders, and neuropsychiatric diseases including de-
mentia were regarded as noncardiovascular causes. Death due to
cardiovascular mortality was classiﬁed as International Classiﬁca-
tion of Diseases, 10th revision codes I00eI99 and death due to other
reasons recorded as noncardiovascular mortality.
2.4. Statistical analysis
Baseline characteristics of the study participants are reported as
mean (standard deviation) for continuous variables and number
(percentage) for categorical variables. Differences in characteristics
of study participants in tertiles of WMH progressionwere tested by
analysis of variance for continuous variables and Pearson c2 test
for categorical variables. In the whole group and in tertiles of
WMH progression, all-cause, cardiovascular, and noncardiovascular
mortality rates were calculated by dividing number of events to
person-years at risk. To compare cumulative incidence of all-cause,
noncardiovascular, and cardiovascular mortality in tertiles of WMH
progression, Kaplan-Meier graphs were made and strata were
compared with log-rank tests. We used Cox proportional hazard
models to estimate risk of all-cause, noncardiovascular, and car-
diovascular mortality associated with level of WMH progression.
Cox regression models were ﬁt with time to death as the outcome
variables and WMH progression (mL/y) as the determinants. The
analyses were conducted in 3 steps. In the ﬁrst step, analyses were
performed without any adjustment. In the second step, analyses
were adjusted for age and sex, and in the ﬁnal model analyses were
adjusted for age, sex, education, body mass index, smoking, serum
cholesterol, systolic blood pressure, antihypertensive medication,
diabetes mellitus, statin treatment, history of vascular diseases
(peripheral, cardiac, and cerebral), and WMH volume at baseline.
Similarly, in a 3-step analysis, using linear regression models, we
calculated the unadjusted and adjusted gray matter volumes in
thirds of total WMH progression. In a sensitivity analysis, we
excluded subjects who developed cardiovascular events and stroke
between 2 MRI measurements to see whether the associations
were independent of these events. All the analyses were carried out
using SPSS software (version 20.0.0, SPSS Inc, Chicago, IL, USA).
3. Results
Mean age of participants was 74.5-year-old and 56.4% of them
were male. Participants with more rapid progression of WMHwere
older (p< 0.001). The remainder of demographic and cardiovascularCardiovascular-related Noncardiovascular-related
HRa (95% CI) p-value HRa (95% CI) p-value
1.30 (1.11e1.53) 0.001 1.24 (1.09e1.41) 0.001
1.31 (1.10e1.55) 0.002 1.24 (1.09e1.42) 0.001
1.29 (1.06e1.56) 0.011 1.20 (1.02e1.40) 0.026
yperintesities.
lic blood pressure, antihypertensive medication, diabetes mellitus, statin treatment,
Table 3
Risk of mortality in relation to progression of periventricular white matter hyperintensities
Mortality
All-cause Cardiovascular-related Noncardiovascular-related
HRa (95% CI) p-value HRa (95% CI) p-value HRa (95% CI) p-value
Unadjusted model 1.26 (1.14e1.40) <0.001 1.24 (1.03e1.50) 0.021 1.28 (1.12e1.45) <0.001
Age and sex adjusted model 1.27 (1.14e1.40) <0.001 1.24 (1.02e1.51) 0.032 1.28 (1.12e1.47) <0.001
Multivariable adjusted modelb 1.22 (1.08e1.37) 0.001 1.22 (0.97e1.50) 0.090 1.24 (1.06e1.44) 0.007
a Hazard ratios (HRs) are calculated for each mL/y progression in periventricular white matter hyperintensities.
b Adjusted for age, sex, education, body mass index, smoking, serum cholesterol, systolic blood pressure, antihypertensive medication, diabetes mellitus, statin treatment,
history vascular diseases, and baseline periventricular white matter hyperintensities.
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progression (all p > 0.05) (Table 1).
During follow-up period, 264 (49.4%) subjects died of whom 83
subjects died of cardiovascular causes and 179 subjects died of
noncardiovascular causes. For 2 subjects causes of death were
not identiﬁed. Incidence rates of all-cause, cardiovascular, and
noncardiovascular mortality were 55.6, 17.5, and 37.7 per 1000
person-years, respectively. Total numbers of deaths in the low,
middle, and high tertiles of WMH progression were 71 (26.9%),
85 (32.2%), and 108 (40.9%), respectively. Fig. 1 shows cumulative
all-cause, cardiovascular, and noncardiovascular mortality in rela-
tion to tertiles of total WMH progression. In the multivariable
adjusted model, each mL/y higher progression of total WMH was
associatedwith 1.22-fold (95% CI: 1.09e1.37) higher risk of all-cause
mortality. Each mL/y higher progression of total WMH was asso-
ciated with 1.29-fold (95% CI: 1.06e1.56) higher risk of cardiovas-
cular mortality and 1.20-fold (95% CI: 1.02e1.40) higher risk of
noncardiovascular mortality (Table 2).
In the multivariable adjusted model, each mL/y higher pro-
gression of periventricular WMH was associated with 1.22-fold
(95% CI: 1.08e1.37) higher risk of all-cause mortality (Table 3).
Despite a signiﬁcant association between periventricular WMH
progression and cardiovascular mortality in the crude and mini-
mally adjusted models, we found no signiﬁcant association in the
multivariable model. In contrast, in the multivariable model, each
mL/y higher progression of periventricular WMH was signiﬁcantly
associated with 1.24-fold (95% CI: 1.06e1.44) higher risk of non-
cardiovascular mortality.
There was no signiﬁcant association between progression of
deep cortical WMH and all-cause mortality (Table 4). Similarly,
progression of deep cortical WMH was not associated with non-
cardiovascular mortality. However, each mL/y higher progression
of deep cortical WMH was associated with 1.92-fold (95% CI:
1.12e3.30) higher risk of cardiovascular mortality.
In an extra analysis, we tested whether more rapid progression
of totalWMHwas associatedwith lower graymatter volumes in the
follow-up MRI session. We observed that in the unadjusted model
accelerated progression of WMH was associated with lower gray
matter volume. However, after further adjustment for demographicTable 4
Risk of mortality in relation to progression of deep cortical white matter hyperintensitie
Mortality
All-cause
HRa (95% CI) p-value
Unadjusted model 1.37 (0.97e1.94) 0.073
Age and sex adjusted model 1.39 (0.98e1.98) 0.063
Multivariable adjusted modelb 1.26 (0.90e1.76) 0.180
a Hazard ratios (HRs) are calculated for each mL/y progression in subcortical white m
b Adjusted for age, sex, education, body mass index, smoking, serum cholesterol, systo
history vascular diseases, and baseline deep cortical white matter hyperintensities.and cardiovascular factors, progression of WMHwas not associated
with level of gray matter volumes (Supplementary Table 6). To test
whether the associations betweenWMH progression and mortality
outcomes were independent of cardiovascular and stroke events
occurred between 2 MRI measurements, we performed a restricted
analysis excluding subjects who developed cardiovascular events
(n ¼ 56) or stroke (n ¼ 26) between 2 MRI measurements. This
restricted analysis showed that exclusion of subjects with events
did not essentially change the associations (Supplementary
Tables 2e5).
4. Discussion
In this prospective study, we showed that accelerated progres-
sion of WMH is linked with subsequent risk of mortality in older
subjects at risk for cardiovascular disease. We observed that pro-
gression of periventricular WMH was signiﬁcantly associated with
noncardiovascular mortality whereas progression of deep cortical
WMH was associated with cardiovascular mortality.
There are a number of prospective studies that investigated the
association between presence and volume ofWMHwith future risk
of mortality. Bokura et al., showed that in neurologically normal
adults, with mean age of 58-year-old, periventricular and not deep
cortical WMH are associated with higher risk of mortality (Bokura
et al., 2006). In an analyses from the Framingham Offspring Study
(mean age 62-year-old), participants with higher total WMH vol-
umewere shown to be at higher risk of mortality during 5.6 years of
follow-up (Debette et al., 2010). Similarly, Ikram et al., showed that
in community dwelling older adults higher global WMH volumes
were related to higher risk of stroke and mortality (Ikram et al.,
2009). All these studies measured WMH once and did not report
whether accelerated progression of WMH associates with higher
risk of mortality in old age. Because single measurement ofWMH in
older age may reﬂect long-standing exposure to cardiovascular risk
factors and inﬂammatory process, it is unclear whether develop-
ment of newWMH in older adults is also of clinical signiﬁcance. In
this long-term follow-up study among subjects >70 years with
repeated measurements of WMH, we demonstrated that acceler-
ated accumulation of WMH detected on brain MRI, independent ofs
Cardiovascular-related Noncardiovascular-related
HRa (95% CI) p-value HRa (95% CI) p-value
2.06 (1.35e3.16) 0.001 0.90 (0.52e1.54) 0.693
2.05 (1.32e3.17) 0.001 0.92 (0.53e1.59) 0.764
1.92 (1.12e3.30) 0.017 0.92 (0.58e1.46) 0.736
atter hyperintensities.
lic blood pressure, antihypertensive medication, diabetes mellitus, statin treatment,
B. Sabayan et al. / Neurobiology of Aging 36 (2015) 2130e21352134baseline WMH volume and cardiovascular status and events,
associates with future risk of all-cause, cardiovascular, and non-
cardiovascular mortality.
Different explanations can be put forward for the association
between WMH progression and risk of mortality. First, this asso-
ciation could be due to shared sociodemographic and vascular risk
factors. However, in this study, we have seen that factors such as
age, education, history of cardiovascular risk factors, and vascular
events did not inﬂuence the associations. Another explanation
could be that accelerated progression of WMH mirrors accelerated
vascular damage in the whole body which puts subjects at risk of
death. This explanation can particularly describe higher risk of
cardiovascular mortality in relation to deep cortical WMH. Previous
reports have also shown that deep cortical WMH are stronger
predictors for manifestations of cerebral small vessel disease such
as lacunar infarcts (Gouw et al., 2008). White matter integrity plays
a crucial role in normal functioning of the brain (Chanraud et al.,
2010). Several complex activities of the brain are coordinated
with close interactions between different regions of the brain
(Greicius et al., 2003). The brain is involved not only in cognitive,
sensory, and motor functions but also in regulation of homeostasis
through endocrine and autonomic systems (Ulrich-Lai and Herman,
2009). Therefore, one explanation could be that accelerated
changes in the brain might inﬂuence the whole body which ulti-
mately increases risk of cardiovascular and noncardiovascular
mortality. Although the latter explanation seems plausible, we
cannot infer it merely from our observational data, and future work
is needed to address how impaired white matter integrity affects
homeostasis in the body. Collectively, it seems that no single
mechanism can explain the observed associations.
Differential associations of periventricular and deep cortical
WMH with noncardiovascular and cardiovascular mortality might
reinforce ﬁndings of previous studies which showed that WMH in
different brain regions have different pathophysiology as well as
clinical consequences (Sachdev and Wen, 2005). It has been sug-
gested that periventricular WMH are more likely to develop
because of chronic hemodynamic abnormalities, whereas deep
WMH are more likely to be related to ischemic changes because of
atherosclerosis or embolic events (Kim et al., 2008). Areas where
periventricular WMH are located receive their blood supply from
noncollateralizing ventriculofugal arteries which makes them
vulnerable to vascular insufﬁciency and decline in cerebral blood
ﬂow (Mandell et al., 2008; ten Dam et al., 2007). In older subjects,
several studies have shown that risk of cognitive impairment is
preferentially associated with periventricularWMH compared with
deep cortical WMH (Debette and Markus, 2010). Conversely,
depressive symptoms in old age have closer relation with deep
cortical WMH rather than periventricular WMH (Thomas et al.,
2002) which supports an ischemic basis for the link between
deep cortical WMH andmood disorders. Despite these evidences, it
should be emphasized that detailed information on speciﬁc causes
of mortality is needed to better understand the mechanisms
underlying the association of periventricular WMH with non-
cardiovascular mortality and the association of deep WMH with
cardiovascular-related deaths.
Certain strengths and limitations of this study need to be
acknowledged. Strengths of this study include long follow-up time,
repeated measurements of WMH, and availability of data for a wide
range of cardiovascular factors. As a limitation, we included older
subjects at risk for cardiovascular disease which might limit
extrapolation of the ﬁndings to general population of older sub-
jects. Although a high proportion of older subjects have history of
cardiovascular diseases or risk factors (Yusuf and Ounpuu, 2003),
future research are needed to test this research question in
population-based studies. As another limitation, because of limitednumber of participants, we were only able to categorize the causes
of mortality into 2 broad groups of cardiovascular and non-
cardiovascular mortality. Certainly, study of larger populations can
provide the opportunity to speciﬁcally address the potential links
between WMH accumulation and speciﬁc causes of death. It has
been shown that development of WMH is preceded by micro-
structural changes in white matter which can be detected with
diffusion tensor imaging studies (Salat et al., 2005). Therefore,
further studies need to address whether accelerated impairment in
white matter integrity even before presence of WMH is related to
adverse clinical outcomes and mortality.
In conclusion, we found that rapid progression of WMH iden-
tiﬁed on brain MRI is associated with higher risk of all-cause,
cardiovascular, and noncardiovascular mortality in old age. These
associations were independent of conventional cardiovascular risk
factors and baseline load of WMH. These ﬁndings suggest that
progression of WMH is an independent risk indicator for mortality
in old age and, in addition to volume of WMH, location of WMH
might guide clinicians toward speciﬁc strategies to prevent mor-
bidities and mortalities in older subjects.
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